Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

And this time, it’s not just fringe actors fanning the flames. It’s policymakers. It’s media personalities. It’s individuals ...

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

The Trump administration’s new vaccine advisers endorsed this fall's flu vaccines late last week, but only those that don't ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...

The preservative thimerosal started Robert F. Kennedy Jr. down the path of questioning vaccine safety. A panel of experts he ...

Dr. Levi and Vicky Pebsworth, a nurse affiliated with an anti-vaccine group, voted against recommending clesrovimab; the ...

As America grapples with one of the worst flu outbreaks in recent years, researchers are hoping to close in on a stronger ...

At first, the monovalent influenza A (H5N8) vaccine will be tested in two doses, 21 days apart, in adults aged 18–59.